The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo


Abstract

The epidermal growth factor receptor (EGFR) and ErbB-2 transmembrane tyrosine kinases are currently being targeted by various mechanisms in the treatment of cancer. GW2016 is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC_{50} values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively. This report describes the efficacy in cell growth assays of GW2016 on human tumor cell lines overexpressing either EGFR or ErbB-2: HN5 (head and neck), A-431 (vulva), BT474 (breast), CalU-3 (lung), and N87 (gastric). Normal human foreskin fibroblasts, nontumorigenic epithelial cells (HB4a), and nonoverexpressing tumor cells (MCF-7 and T47D) were tested as negative controls. After 3 days of compound exposure, average IC_{50} values for growth inhibition in the EGFR- and ErbB-2-overexpressing tumor cell lines were <0.16 μM. The average selectivity for the tumor cells versus the human foreskin fibroblast cell line was 100-fold. Inhibition of EGFR and ErbB-2 receptor autophosphorylation and phosphorylation of the downstream modulator, AKT, was verified by Western blot analysis in the BT474 and HN5 cell lines. As a measure of cytotoxicity versus growth arrest, the HN5 and BT474 cells were assessed in an outgrowth assay after a transient exposure to GW2016. The cells were treated for 3 days in five concentrations of GW2016, and cell growth was monitored for an additional 12 days after removal of the compound. In each of these tumor cell lines, concentrations of GW2016 were reached where outgrowth did not occur. Furthermore, growth arrest and cell death were observed in parallel experiments, as determined by bromodeoxyuridine incorporation and propidium iodide staining. GW2016 treatment inhibited tumor xenograft growth of the HN5 and BT474 cells in a dose-responsive manner at 30 and 100 mg/kg orally, twice daily, with complete inhibition of tumor growth at the higher dose. Together, these results indicate that GW2016 achieves excellent potency on tumor cells with selectivity for tumor versus normal cells and suggest that GW2016 has value as a therapy for patients with tumors overexpressing either EGFR or ErbB-2.

Introduction

The EGFR2 and ErbB-2 are members of the type I receptor tyrosine kinase family and have been investigated as potential targets for cancer therapy because of their overexpression in a variety of neoplastic tissues (1). With the exception of ErbB-3, which acts as a noncatalytic partner to other erbB family members, the type I receptors have functional tyrosine kinase catalytic domains. When ligand binds to type I receptors, dimerization occurs. This causes a conformational change in the receptor that activates the kinase domain and results in autophosphorylation and initiation of divergent signal transduction cascades (2). Whereas ErbB-2 is generally thought to be orphaned from a high-affinity ligand, it participates in signaling by heterodimerization with ligand-bound members of the type I receptor family. EGFR and ErbB-2 are known to signal through the Ras pathway, stimulating cell division (3), and through the PI3K pathway, resulting in cell growth and survival (1). Because these effects on cell growth and survival are dependent on the catalytic activity of EGFR and ErbB-2, it is believed that inhibition of this activity could provide a therapeutic opportunity for patients with tumors expressing elevated levels of EGFR and ErbB-2.

Recent efforts to design small molecule inhibitors of EGFR have generated encouraging preclinical and clinical results (2–8). We have reported previously the discovery of a number of small molecule, dual EGFR/ErbB-2, tyrosine kinase inhibitors with activity in preclinical tumor models (9, 10). This study describes the activity of a novel small molecule, GW2016, on normal and tumor-derived human cells in cul-

1 To whom requests for reprints should be addressed, at Department of Cancer Biology, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709.

2 The abbreviations used are: EGFR, epidermal growth factor receptor; PI3K, phosphatidylinositol 3-kinase; HTRF, homogenous time resolved fluorescence; MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase; HFF, human foreskin fibroblast; RIPA, radioimmunoprecipitation assay; v/v, volume for volume; w/v, weight for volume; TBST, Tris-buffered saline plus Tween 20; FBS, fetal bovine serum; BrdUrd, bromodeoxyuridine.
ture and in human tumor xenograft models. GW2016 is a potent inhibitor of EGFR and ErbB-2 tyrosine kinase catalytic activity and is selective for EGFR and ErbB-2 versus other proline-kinase inhibitors. Treatment of cell lines with GW2016 results in potent inhibition of tumor cell growth, increased tumor cell death, and selectivity for growth inhibition of tumor cell lines versus normal cells.

Materials and Methods

Synthesis. GW2016, N-(3-Chloro-4-[(3-fluorobenzoyl)oxy]-phenyl)-5-[6-[[2-(methylsulfonyl)ethyl][amino][methyl]-2-furyl]-4-quinazolinamine, was synthesized as described (11). OSI-774, [6,7-bis(2-methoxy-ethoxy)quinazoline-4-yl]-[3-ethylphenyl]amidine, was synthesized as described (12). ZD1839, 4-(3-chloro-4-fluoro-anilino)-7-methoxy-6-(3-morpholinopropoxy) quinazoline, was synthesized as described (13).

In Vitro Kinase Assays. The intracellular kinase domains of EGFR, ErbB-2, and ErbB-4 were purified from a baculovirus expression system. EGFR, ErbB-2, and ErbB-4 reactions were performed in 96-well polystyrene round-bottomed plates in a final volume of 45 μL. Reaction mixtures contained 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 2 mM MnCl₂, 10 μM ATP, 1 μCi of [γ-33P]ATP/reaction, 50 μM Peptide A [Biotin-(6-amino caproic acid)-EERIEFELVAKKKamide, Quality Controlled Biochemicals, Inc.], 1 mM dithiothreitol, and 1 μL of DMSO containing serial dilutions of GW2016 beginning at 10 μM. The reaction was initiated by adding the indicated purified type-1 receptor intracellular domain. The amount of enzyme added was 1 pmol/reaction (20 nM). Reactions were terminated after 10 min at 23°C by adding 45 μL of 0.5% phosphoric acid in water. The terminated reaction mix (75 μL) was transferred to phosphocellulose filter plates (Millipore, Marlborough, MA). The plates were filtered and washed three times with 200 μL of 0.5% phosphoric acid scintillant cocktail (50 μL, Optiphase; Wallac) added to each well, and the assay was quantified by counting in a Packard TopCount (Packard Instrument Co.).

The catalytic domains of vascular endothelial growth factor receptor 2, c-Fms, c-Src, CDK1, CDK2, and Tie-2 were expressed and purified using the baculovirus expression system. Kinase assays were performed as described above with the following modifications. c-Fms assays contained: 10 μM enzyme, 50 mM 4-morpholinepropanesulfonic acid (pH 7.5), 10 mM MgCl₂, 20 μM ATP, and 200 μM Peptide A. The reaction was allowed to proceed for 30 min, terminated, and quantified as described above. Vascular endothelial growth factor receptor 2 assays contained: 10 μM enzyme, 100 μM HEPES (pH 7.5), 0.1 mg/ml BSA fraction V (Sigma Chemical Co., St. Louis, MO), 0.1 mM DTT, 360 nM peptide A, 7.5 μM ATP, and 5 mM MgCl₂. The reaction was allowed to proceed for 40 min. Product was detected using an HTRF procedure (14). Briefly, the reactions were quenched by adding 100 μL of 100 mM HEPES (pH 7.5), 100 mM EDTA, 45 mM streptavidin-linked-allophycocyanin ( Molecular Probes), and 3 mM europium-conjugated antiphosphotyrosine antibody (Wallac). Product was detected using a Victor plate reader (Wallac) with a time delay at 665 nm. cSrc assays contained: 0.4 μM Enzyme, 100 mM HEPES, and 100 μM peptide substrate [Biotin-(6-amino caproic acid)-AAAOIQGYQI-NH₂; Quality Controlled Biochemicals, Inc.]. The reaction was allowed to proceed for 40 min, and product was detected using the HTRF procedure. CDK1 and CDK2 assays contained: 100 μM HEPES (pH 7.5), 10 mM MgCl₂, 0.1% BSA, 0.5 μCi of [γ-33P]ATP, 1.4 μM ATP (2 μg/ml), CDK1 (1 μg/ml), and CDK2, and 1.5 μM Biotin-amino hexyl-ARRPMSPKKKACONH₂ (Quality Controlled Biochemicals, Inc.). Reactions were initiated as described above and allowed to proceed for 30 min. Reactions were terminated with 100 μL of 50 mM HEPES (pH 7.5) and 100 mM EDTA and allowed to proceed for 20 (CDK2) or 60 min (CDK1). Reactions were terminated by the addition of 20 μL of 250 mM EDTA in PBS 7.0. Next, 180 μL of Streptavidin SPA beads (Amersham) were added, the plates were sealed, and the beads were allowed to settle for at least 8 h, then the plate was counted.

Tie-2 was preactivated by incubation in the presence of 2 μM ATP, 5 mM MgCl₂, 12.5 mM DTT, and 0.1 mM HEPES (pH 7.5) at room temperature for 30 min before it was diluted properly to make up the enzyme mixture. Tie-2 assays contained: 1 μM Biotin-C6-LEARLVAEYGWWGKHKamide (Synpep Corp.), 80 μM ATP, 0.05 mM BSA, 100 mM HEPES (pH 7.5), 10 mM MgCl₂, 1 mM DTT, and 10 mM Tie-2. Product was detected using HTRF as described above.

MEK-6 and p38 were expressed and purified in an Escherichia coli expression system. MEK6-activated p38 was purified, and its ability to phosphorylate Biotin-IPTSPITTTY-FFRRR-amide (Quality Controlled Biochemicals, Inc.) in the presence or absence of GW2016 was measured in a scintillation proximity assay. p38 assays contained: 100 mM HEPES (pH 7.5), 10 mM MgC₂H₂O₄, 0.08 μCi/well [γ-33P]ATP, 1.5 μM ATP, 1.5 μM Biotin-IPTSPITTTY-FFRRR-amide, 120 mM MEK6-activated p38, and 6% DMSO. Reactions were allowed to proceed for 60 min at room temperature and quenched with the addition of 50 μL of 250 mM EDTA and mixed with 150 μL of avidin SPA beads (Amersham) to 0.5 mg/reaction. The plates were sealed, and the beads were allowed to settle overnight. The plates were counted in a Packard TopCount for 60 s.

The ability of GW2016 to inhibit the c-Raf-1, MEK, and extracellular signal-regulated kinase cascade was determined as described previously (14).

Cells and Cell Culture. Normal HFFs were isolated by digesting human neonatal foreskins with a solution of 2.5% trypsin and 1 mM EDTA. The LICR-LON-HN5 head and neck carcinoma cell line (HN5) was a gift from Helmut Modjtahedi at the Institute of Cancer Research, Surrey, United Kingdom. The breast carcinoma cell lines, BT474, MCF-7, and T47D; the vulva carcinoma cell line, A-431; and the gastric carcinoma cell line, NCI-N87 (N87); were obtained from the American Type Culture Collection (Rockville, MD). HFF, HNS, and N87 were maintained by subculturing in 75-cm² tissue culture flasks in low-glucose DMEM containing 10% FBS (HyClone) until ready for use. MCF-7 cells were maintained in high-glucose DMEM containing 10% FBS. BT474 cells were maintained in either DMEM or RPMI 1640 supplemented with 10% FBS. T47D, A-431, and CaLu-3 cells were maintained in RPMI supplemented with 10% FBS. HB4a and HB4a c5.2 cells were generated as described (15) and were maintained

Downloaded from mct.aacrjournals.org on June 20, 2017. © 2001 American Association for Cancer Research.
in RPMI 1640 supplemented with 10% FBS, 5 μg/ml hydrocortisone, 5 μg/ml insulin, and 50 μg/ml hygromycin B.

**Immunoprecipitation and Western Blot Analysis.** Cells were plated in 150-cm² tissue culture plates in the appropriate growth medium (BT474 = RPMI, HN5 = DMEM containing 10% FBS). When cells were in logarithmic growth (40–80% confluence), growth medium was aspirated and replaced with the appropriate growth medium containing either vehicle (0.1% DMSO), 0.03, 0.1, 0.3, 1, 3, or 10 μM GW2016. Treated cells were returned to the incubator for 6 h. The medium was then removed, and cells were rinsed once with cold PBS (#14190–144; Life Technologies, Inc., Grand Island, NY) and lysed in 1 ml of RIPA [150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 0.25% deoxycholate, and 1% NP-40] containing protease inhibitor cocktail (Roche) and 1 mM sodium orthovanadate (RIPA +).

EGFR was immunoprecipitated from 0.25 mg of HN5 lysate or 1 mg of BT474 lysate. HN5 and BT474 lysates were diluted to 0.75 and 1 ml, respectively, with RIPA + and were precleared with 30 μl of Protein G Plus/Protein A agarose suspension for 30 min at 4°C. Precleared lysates were transferred to new tubes, and 4 (for HN5) or 10 μl (for BT474) of anti-EGFR Ab-13 (Lab Vision) were added. Tubes were incubated at 4°C for ≥2 h to allow complex formation. Protein G Plus/Protein A (30 ml) was added to each tube, and samples were incubated overnight at 4°C. Beads were spun down and washed once with RIPA, once with RIPA containing 0.1% SDS (RIPA-SDS), and once with PBS. Beads were resuspended in 20 μl of SDS-PAGE sample buffer.

ErBB2 was immunoprecipitated from 0.25 mg of BT474 lysate or 1 mg of HN5 lysate, diluted with 0.75 or 1 ml RIPA +, respectively, and precleared as described above. Precleared lysates were transferred to new tubes, and 4 (for BT474) or 10 μl (for HN5) of anti-c-neu Ab-3 (Oncogene Research Products) were added. Complex formation, precipitation, and washes were carried out as described above.

Samples were boiled for 5 min before being loaded on 6% NOVEX gels (1.5 mm, 15 lanes). After electrophoresis, samples were transferred to nitrocellulose using standard Western blotting procedures, and the nitrocellulose membranes were blocked in TBST [150 mM NaCl, 10 mM Tris-HCl, and 0.1% (v/v) Tween 20 (pH 7.5)] containing 4% (w/v) BSA. Membranes were incubated in anti-pTyr monoclonal antibody PT66 (Sigma Chemical Co.) diluted 1:5000 in the TBST/BSA blocking buffer for 1–2 h at room temperature or overnight at 4°C. They were then rinsed twice in TBST, followed by three 20-min washes. Next, membranes were incubated in horseradish-peroxidase-conjugated antimouse secondary antibody diluted 1:100,000 (Jackson Immunoresearch) in TBST/BSA blocking buffer for 1 h at room temperature or overnight at 4°C. The membranes were washed as described above and were incubated in SuperSignal West Femto Detection Reagent (supplier) for 1 min. After blotting dry, membranes were placed in a sheet protector and exposed to film.

For densitometric analysis of EGFR and ErBB2 phosphorylation, films were scanned on a Bio-Rad Fluor-S MultiImager, and relevant bands were quantified using Quantity One quantitation software. Concentrations that inhibit 50% of tyrosine phosphorylation (IC₅₀) were interpolated using the method of Levenberg and Marquardt (16) and this equation: 

\[ y = V_{\text{max}} \times \frac{1}{1 + \left(\frac{x}{K_x} \times (c^x + c^y)\right)} \]

where “K” is equal to IC₅₀.

For phosphoserine AKT immunoblotting, the RIPA + lysates described above (20 μg of total protein) were run on 10% Tris-glycine gels (Novex/Invitrogen), transferred to nitrocellulose, blotted with an antiphospho-AKT-Ser (473) antibody (cat # 9271; Cell Signaling Technology), and diluted 1:1000 in 1% milk/TBST. Membranes were washed in TBST as described above and blotted with horseradish peroxidase-conjugated donkey antirabbit secondary antibody, diluted 1:10,000 in 1% milk/TBST. The membranes were washed again, as described above, and detection was performed with enhanced chemiluminescence (Amersham) using the method recommended by the manufacturer.

**In Vitro Growth Inhibition Assays.** For assessment of cell-based potency, cells were plated in 96-well Falcon plates (Becton Dickinson) in the growth media described above. Plating densities that resulted in logarithmic growth of vehicle-treated cells for the duration of the assay were used: HFF, 15,000 cells/cm²; BT474, MCF-7, N87, and Calu-3, 30,000 cells/cm²; and HN5, A-431, T47D, HB4a, and HB4a c5.2, 10,000 cells/cm². After 24 h, cells were exposed to compounds at the concentrations indicated in Fig. 2. HFF, BT474, HN5, and N87 cells were treated in low-glucose DMEM containing 5% FBS, 50 μg/ml gentamicin, and 0.3% v/v DMSO. MCF-7 cells were treated in 50% high-glucose DMEM, 50% low-glucose DMEM containing 5% FBS, 50 μg/ml gentamicin, and 0.3% v/v DMSO. T47D, A-431, and Calu-3 cells were treated in 50% RPMI, 50% low-glucose DMEM containing 5% FBS, 50 μg/ml gentamicin, and 0.3% v/v DMSO. HB4a and HB4a c5.2 cells were treated in 50% DMEM, 50% RPMI 1640 supplemented with 5% FBS, 2.5 μg/ml hydrocortisone, 2.5 μg/ml insulin, 25 μg/ml hygromycin B, 50 μg/ml gentamicin, and 0.3% v/v DMSO. After 3 days, relative cell number was estimated using methylene blue staining. The media were removed, and 100 μl of 0.5% w/v methylene blue dissolved in 50% ethanol and 50% water were added to each well. Plates were washed by immersion in deionized water and allowed to air dry. 1% w/v n-lauroyl-sarcosine (100 μl) dissolved in PBS was added to each well, and plates were incubated for 30 min at room temperature. The absorbance at 620 nm was read in a Spectra (Tecan) microplate reader. Data were analyzed using curve-fitting macros written for Microsoft Excel. Concentrations with IC₅₀ were interpolated using the method of Levenberg and Marquardt and this equation: 

\[ y = V_{\text{max}} \times \frac{1}{1 + \left(\frac{x}{K_x} \times (c^x + c^y)\right)} \]

where “K” is equal to IC₅₀.

**Outgrowth Assays.** Cells were plated in 96-well plates, in the media described above, at the following densities: HFF and HN5, 1000 cells/well and BT474, 5000 cells/well. After 24 h, the cells were exposed to vehicle (0.3% DMSO) or GW2016 as described above, at the concentrations indicated in Fig. 3. Compound was removed from the cells after 24 h, the cells were exposed to vehicle (0.3% DMSO) or GW2016 as described above, at the concentrations indicated in Fig. 3. Compound was removed from the cells after 24 h, the cells were exposed to vehicle (0.3% DMSO) or GW2016 as described above, at the concentrations indicated in Fig. 3.
Effects of EGFR/ErbB-2 Tyrosine Kinase Inhibitor, GW2016

Cell Cycle Analysis. BT474 and HN5 cells were plated in six-well tissue culture plates at 2 x 10^6 (BT474) and 1 x 10^5 (HN5) cells/well. After 24 h, cells were treated with vehicle (0.1% DMSO) or GW2016 at the concentrations indicated. After 3 days of compound exposure, cells were labeled for 1 h with 10 μM BrdUrd, rinsed with PBS, and harvested by trypsinization. The PBS and trypsin rinses were reserved and combined with the trypsinized cells. Cells were pelleted by centrifugation at 500 x g for 5 min. Supernatant was aspirated, and pellets were dissociated by vortexing and fixed by dropwise addition of ice-cold 70% methanol while vortexing. Cell death and cell cycle analysis were assessed by propidium iodide staining and antibody detection of incorporated BrdUrd and staining with propidium according to the manufacturer’s directions (Becton Dickinson).

In Vivo Studies. CD-1 nude female mice and C.B-17 SCID female mice (4–6 weeks old) were purchased from Charles River Laboratories (Wilmington, MA) and housed in microisolator cages. The research complied with national legislation and with company policy on the Care and Use of Animals and related codes of practice. All animal handling was done in a laminar flow hood. CD-1 nude female mice were used for HN5 human tumor xenografts, which were initiated by injection of a cell suspension in PBS:Matrigel (1:1). C.B-17 SCID female mice were used for BT474 human tumor xenografts, which were initiated by implantation of tumor fragments (20–100 mg) from established tumors. Tumor cells and fragments were implanted by s.c. injection in the right flank. The s.c. tumors were measured with calipers, and mice were weighed twice weekly. Tumor weight was estimated from tumor volume using this formula: length x width²/2 = tumor volume (mm³). Treatment began when tumors were palpable, ~3–5 mm in diameter. Experimental compouds were administered p.o. twice daily for 21 days in a vehicle of sulfo-butyl-ether-β-cyclodextrin 10% aqueous solution (CD10).

Results

In Vitro Inhibition of Kinase Activity by GW2016. Table 1 contains the structure and IC₅₀ values for the inhibition of enzyme activity for GW2016. GW2016 is a 4-anilino, 6-substituted quinazoline with potent activity against both EGFR and ErbB-2 in vitro. The IC₅₀ values for inhibition of enzyme activity were generated by measuring inhibition of phosphorylation of a peptide substrate. With the exception of ErbB-4, GW2016 was >300-fold selective for EGFR and ErbB-2 over other kinases tested.

Inhibition of Receptor Autophosphorylation in Cells. The ability of GW2016 to inhibit the activity of EGFR and ErbB-2 in intact cells was assessed by immunoprecipitation and Western blot analysis (Fig. 1). Receptor phosphorylation and protein levels were measured in HN5 and BT474 cells after 6 h of compound exposure. Receptors were immunoprecipitated using either EGFR or ErbB-2 antibodies and blotted for phosphotyrosine content. Treatment with GW2016 inhibited receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Averaged IC₅₀ values are presented in Table 2. Expression of EGFR or ErbB-2 protein was not inhibited (data not shown). The ability of GW2016 to inhibit EGFR and ErbB-2 autophosphorylation in EGFR- and ErbB-2-overexpressing tumor cells is ~10-fold less than its potency on the purified enzyme. This effect has precedent with reversible quinazoline tyrosine kinase inhibitors (2, 16) and is likely attributable to competition from intracellular levels of ATP.

In Vitro Growth Inhibition. The ability of GW2016 to inhibit the growth of human tumor cells was assessed in a cell-based proliferation assay using protein staining as an estimate of relative cell number (Fig. 2 and Table 3). The cell-based assay included EGFR-overexpressing cell lines HN5 (17) and A-431 (18); the ErbB-2-overexpressing cell lines BT474 (19), N87 (20), and CaLu-3 (21); and tumor cell lines expressing low levels of EGFR and ErbB-2, MCF-7 (22), and T47D (23). The IC₅₀ values were interpolated from 10-point dose-response curves using Levenberg-Marquardt nonlinear regression. Treatment with GW2016 resulted in IC₅₀ values of ~0.16 μM on the EGFR- and the ErbB-2-overexpressing tumor cell lines. The ability of GW2016 to inhibit the growth of tumor cells overexpressing EGFR or ErbB-2 was compared with the EGFR selective inhibitors, OSI-774 and Iressa (Table 3). GW2016 inhibits the growth of...
both EGFR- and ErbB-2-overexpressing cells, whereas OSI-774 and Iressa preferentially inhibit the growth of the EGFR-overexpressing cell lines. When compared with EGFR- and ErbB-2-overexpressing cell lines, GW2016 was less effective at inhibiting the growth of breast tumor cell lines expressing low levels of EGFR and ErbB-2, MCF-7, and T47D. IC_{50} values for these cell lines were -3 μM and were -25-fold higher than IC_{50} values for the EGFR- or ErbB-2-overexpressing cell lines. Selectivity for tumor versus normal tissue was determined by comparing efficacy of GW2016 on tumor cells to efficacy on HFF cells. Using the average of the tumor cell IC_{50} values, GW2016 is ~100-fold more potent on the tumor cell lines than on the normal fibroblast cells.

The selectivity for GW2016 on transformed versus normal epithelial cells was verified in a transfected cell system (Table 3 and Fig. 3). The ErbB-2-transfected mammary epithelial cell line, HB4a c5.2, is ~40-fold more responsive to GW2016 treatment than the untransfected parental control line, HB4a.

Outgrowth Assays. To determine concentrations of GW2016 capable of causing irreversible growth arrest of tumor cell populations, studies using transient exposure to GW2016 followed by outgrowth in the absence of compound were performed (Fig. 4). Cells were exposed to compound at the concentrations indicated for 3 days, followed by outgrowth in the absence of compound for 12 days. In multiple experiments, concentrations were reached where outgrowth after transient drug exposure did not occur. Transient exposure to 30 μM GW2016 results in complete inhibition of outgrowth of the HNS5 cell population after ~2 additional weeks of culture without compound. Inhibition of outgrowth by 50% occurs at concentrations >3.3 μM. Significant inhibition of outgrowth (20%) occurs at doses as low as 0.37 μM (P = 0.001; Fig. 4a). Another EGFR-overexpressing cell line, A-431, responded similarly to HN5 (data not shown). GW2016 was similar to OSI-774 in its ability to inhibit outgrowth of the EGFR-overexpressing cell line (Fig. 4b).

The threshold for complete inhibition of the BT474 cells is 1 μM, with ~60% inhibition of outgrowth occurring at 0.32 μM (P = 0.004; Fig. 4c). Another ErbB-2-overexpressing cell line, N87, responded similarly to BT474 (data not shown). GW2016 is much more effective than OSI-774 at inhibiting the outgrowth of the ErbB-2-overexpressing cell lines (Fig. 4d). Normal fibroblasts are less responsive to GW2016 in the outgrowth assay than the EGFR- or ErbB-2-overexpressing cell lines. Outgrowth of the HFF cell line is not significantly inhibited at concentrations of GW2016 ~10 μM (~10% inhibition at 3.3 μM), and evidence of survival is seen at the 30 μM (Fig. 4e).

Cell Cycle. The effect of GW2016 treatment on the cell cycle of EGFR- and ErbB-2-overexpressing cells was determined by flow cytometric analysis of BrdUrd incorporation...
inhibit the growth of EGFR-overexpressing cell lines is equal to that of the EGFR selective inhibitors, OSI-774 and Iressa. As expected, GW2016 is able to inhibit the growth of ErbB-

and propidium iodide staining. Results are shown in Fig. 5 and Table 4. Treatment of the EGFR-overexpressing cell line, HN5, with 1 and 10 μM GW2016 resulted in induction of G1 arrest. A slight increase in the number of cells with sub-2N DNA content, consistent with cell death by an apoptotic mechanism, was also observed by 72 h with 10 μM GW2016. In the BT474 cells, a large increase in the number of events with sub-2N DNA was observed after 72 h of treatment with GW2016. Apoptosis was confirmed by the detection of disrupted nuclear fragments after staining methanol-fixed cells with 4’,6-diamidino-2-phenylindole (data not shown).

 Effects on Signal Transduction. To correlate the effects of GW2016 on cell growth and survival with specific biochemical effects, we investigated the ability of the compound to inhibit the phosphorylation of key signal transduction mediator AKT (Fig. 6). AKT phosphorylation has been linked to inhibition of apoptotic pathways and, thus, cell survival in a number of systems (1, 24–26). Western blot analysis using a phosphorylation state-specific AKT antibody shows that GW2016 inhibits the phosphorylation AKT in both of the cell lines tested. Although EGFR and ErbB-2 are inhibited similarly in the BT474 and HN5 cells, there are dramatic differences between the amount of inhibition of AKT phosphorylation in response to 6 h of GW2016 treatment. AKT phosphorylation is inhibited to a much greater extent in the BT474 cells than in the HN5 cells, correlating with the ability of GW2016 to initiate cell death (BT474) or growth arrest (HN5) in these cell lines.

Xenograft Growth Inhibition. GW2016 was potent at inhibiting the growth of BT474 and HN5 human tumor xenografts (Fig. 7). A dose-responsive inhibition of both models occurred on treatment of tumor-bearing mice with 30 and 100 mg/kg GW2016 orally, twice daily. Complete inhibition of tumor growth was seen at the 100 mg/kg dose. At this dose, there was <10% weight loss in treated animals over the course of the 21-day treatment (data not shown).

Discussion

GW2016 is a potent inhibitor of EGFR and ErbB-2 kinase activity. Using in vitro cell-based assays and tumor xenograft models, we sought to determine whether GW2016 has potential use in anticancer therapy. We tested GW2016 in the BT474, HN5, N87, CaLu-3, and A-431 tumor cell lines. The BT474, HN5, and A-431 tumor models have proven reliable predictors of compound activity for type I receptor-targeted therapies that have advanced to the clinical setting. These include the currently approved cancer therapy, Herceptin (27, 28), and the small molecule inhibitors OSI-774 (2, 7), Iressa (29), and CI 1033 (30), which are currently in clinical trials.

The data show that GW2016 is potent at inhibiting the growth of a number of EGFR- and ErbB-2-overexpressing cell lines from a variety of tumor types, including the validated models mentioned above. The ability of GW2016 to inhibit the growth of EGFR-overexpressing cell lines is equal to that of the EGFR selective inhibitors, OSI-774 and Iressa. As expected, GW2016 is able to inhibit the growth of ErbB-
2-overexpressing cell lines with more potency than the EGFR-selective inhibitors tested. These and previous data suggest that an inhibitor of both EGFR and ErbB-2 could provide benefit to a wider population of cancer patients than therapies targeted to EGFR or ErbB-2 alone, by including patients expressing high levels of either receptor.

It is generally considered advantageous for anticancer therapy to eliminate cancer cells by differentiation or death as opposed to causing reversible growth arrest (31). Much has been speculated about the ability of type I receptor inhibitors to cause cell cycle arrest versus cell death. Inhibition of EGFR has been linked to both reversible growth arrest (32, 33) and entry into apoptosis (2, 17) in various models. Treatment of cells in culture with ErbB-2 mediators has predominantly been shown to cause reversible growth arrest (34, 35). However, cell death has been shown to occur upon abrogation of ErbB-2 signaling by an antisense oligonucleotide (36) or ribozyme (37). Furthermore, EGFR and ErbB-2 activation have been linked to the PI3K/AKT cell survival pathway, implying that inhibition of EGFR or ErbB-2 catalytic activity should be capable of inducing cell death. We used outgrowth studies to test the ability of transient treatment with GW2016 to inhibit the growth of tumor and normal cells. These studies confirm that above certain concentrations of GW2016, EGFR- and ErbB-2-overexpressing tumor cells cannot continue to proliferate, even after removal of compound. Cell cycle analysis corroborated the outgrowth studies. Evidence of cell death was seen with doses of GW2016 that reduced outgrowth potential in the HN5 and BT474 cell lines.

In the outgrowth and cell cycle assays that we performed, GW2016 proved more effective against ErbB-2-overexpressing cell lines than against EGFR-overexpressing cell lines. We do not know if this differential effect applies to EGFR-overexpressing cell lines in general or if it is unique to the cell lines tested in this study. The data presented suggest that inhibition of EGFR by GW2016 results preferentially in cell growth arrest, whereas inhibition of ErbB-2 yields growth arrest and cell death after 72 h in vitro.

The inhibition of AKT phosphorylation in the two cell lines provides interesting insight into the differential response of the EGFR- and ErbB-2-overexpressing cells to GW2016. The ability of GW2016 treatment of the EGFR-overexpressing cell line, HN5, to down-regulate AKT phosphorylation is limited until concentrations reach 3 μM. HN5 cells primarily undergo reversible growth arrest rather than apoptosis after treatment with GW2016; however, at 10 μM GW2016, there is a significant but incomplete inhibition of outgrowth of the HN5 cells.

---

**Fig. 4.** Growth arrest or cell death in EGFR- or ErbB-2-overexpressing cells caused by treatment with GW2016. Cells were treated for 3 days with GW2016 or OSI-774 (an EGFR-selective inhibitor, used as a positive control), beginning on day 1. GW2016 (or OSI-774) was removed on day 4 and replaced with fresh growth medium. Cells were fed weekly for the duration of the assay. Methylene blue staining was performed at the time points indicated on the graph. Doses of GW2016 resulting in inhibition outgrowth after 3 days of drug exposure were achieved cells that overexpress EGFR (HN5) and ErbB-2 (BT474). Vehicle, 0.37 μM; 1.1 μM; 3.3 μM; 10 μM; and 30 μM.
This is consistent with the ability of GW2016 to induce a low level of apoptosis and reversible growth arrest in this cell line. The cell cycle and outgrowth assay results correspond with the ability of GW2016 to inhibit phosphorylation of AKT in the HN5 cells only at a dose \( \geq 3 \mu M \). Outgrowth studies in the EGFR-overexpressing A431 cell line are similar to the HN5 response. The ErbB-2-overexpressing cell line, BT474, dramatically down-regulates AKT phosphorylation in response to GW2016 treatment at doses as low as 0.3 \( \mu M \). BT474 cells undergo apoptosis after 72 h of GW2016 treatment at 1 or 10 \( \mu M \). Outgrowth of the BT474 cell line is inhibited significantly at doses as low as 0.37 \( \mu M \). Outgrowth assays with another ErbB-2-overexpressing cell line, N87, yielded similar results to the BT474 outgrowth assays. Therefore, ErbB-2-overexpressing tumor cell lines may be highly susceptible to apoptosis on abrogation of receptor activity.

These results are consistent with the finding that inhibition of AKT phosphorylation in the presence of activated p38 is a key mediator of apoptosis after treatment with the irreversible type I receptor inhibitor, CI 1033 (30). Indeed, we show potent down-regulation of AKT phosphorylation in the BT474 cell line, correlating with a considerable induction of apoptosis. Interestingly, the HN5 cell line is growth inhibited by GW2016 with less dramatic effects on AKT phosphorylation. It is possible that mechanisms for activating p38 are not in place in the HN5 cells, thus preventing complete inhibition of AKT activity and maintaining activation of certain AKT-dependent cell survival pathways. The fact that the IC\(_{50}\) for HN5 cell growth is the same as BT474 in the 72-h proliferation assay implies the interruption of an EGFR-dependent proliferation signal in the HN5 cells. Given the interplay between the type I receptors and the PI3K, ras, c-Jun-NH\(_2\)-terminal kinase, and signal transducers and activators of transcription pathways (38, 39), the potential exists for complex interactions which could affect the response of tumors to type I receptor therapy. Unique signaling in EGFR- versus ErbB-2-overexpressing cells should continue to be investigated, with the appreciation that the effects of type I receptor inhibition could also be greatly influenced by the relative levels of the other family members, ErbB-3 and ErbB-4 (40). Furthermore, extensive testing of GW2016 in a variety of cellular systems and investigation of multiple downstream mediators of type I receptors must be completed to define the specific effects of this compound on ErbB-2- or EGFR-overexpressing tumors. Regardless of the intricacies of EGFR and ErbB-2 signaling in cell survival, we have shown that inhibition of either of these enzymes with GW2016 results in interference of growth or survival of cells from many tumor types, overexpressing either EGFR or ErbB-2.

One possible advantage of signal transduction inhibitors compared with conventional cytotoxic chemotherapy is that, by targeting specific molecular dysfunctions in cancer cells, the signal transduction inhibitors may be responsible for fewer side effects and adverse events. Therefore, it was necessary to demonstrate the selectivity of GW2016 for its

### Table 4

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Phase</th>
<th>Vehicle control</th>
<th>1 ( \mu M ) GW2016</th>
<th>10 ( \mu M ) GW2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>BT474</td>
<td>G1</td>
<td>50</td>
<td>70</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>37</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>G2/M</td>
<td>9</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Apoptosis (Sub-2N DNA)</td>
<td>1</td>
<td>18</td>
<td>57</td>
</tr>
<tr>
<td>HN5</td>
<td>G1</td>
<td>51</td>
<td>91</td>
<td>79</td>
</tr>
<tr>
<td></td>
<td>S</td>
<td>39</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>G2/M</td>
<td>8</td>
<td>4</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Apoptosis (Sub-2N DNA)</td>
<td>1</td>
<td>1</td>
<td>8</td>
</tr>
</tbody>
</table>

\( ^a \) Values were determined by gate analysis of flow cytometric plots in Fig. 5 and are presented as a percentage of the total cell population, after eliminating cell doublets. The addition of values for each treatment do not total 100% attributable to the presence of a small population of events appearing outside of the normal cell cycle.

\( ^b \) Apoptotic events are inferred by the presence of cells with <2N DNA.

\( ^c \) Cells were treated for 72 h, followed by flow cytometric analysis.
molecular targets, EGFR and ErbB-2, and for tumor cells that are dependent on the EGFR and ErbB-2 signaling pathways. Attributable to the possibility of confounding results from interdependent signal transduction pathways, we performed selectivity experiments on purified enzymes. Data from in vitro assays show that GW2016 is 300-fold more potent on EGFR and ErbB-2 than a number of other kinases involved in cellular proliferation. Furthermore, we have shown previously that EGFR/ErbB-2 selective inhibitors specifically affect growth of HB4a breast epithelial cells transfected with erbB-2 as compared with Ha-ras transfected HB4a cells (10). We present data that show GW2016 is selective for the erbB-2-transfected cell line relative to the untransfected parental control cell line. The ras-transfected cell line in this system is also much less responsive to GW2016 than the ErbB-2-transfected clone (data not shown). We also present evidence that tumor cells expressing low levels of EGFR and ErbB-2 (MCF-7 and T47D) are 25-fold less responsive to growth inhibition by GW2016. Because it was necessary to verify that GW2016 was inhibiting the EGFR and ErbB-2 kinases intracellularly, we confirmed that GW2016 inhibits the phosphorylation of EGFR and ErbB-2 by immunoprecipitation and Western blot analysis of EGFR and ErbB-2 in cells after treatment with various doses of GW2016. Taken together, these results suggest that the effects of GW2016 in cell growth assays are attributable to specific inhibition of EGFR and ErbB-2 kinase activity, verifying the selectivity of GW2016 and adding to the validation of EGFR and ErbB-2 as targets in anticancer therapy.

Potential cancer therapies must not only inhibit cell growth in vitro but must be able to inhibit tumor growth in the complex in vivo environment. We confirmed that GW2016 is capable of inhibiting the growth of human tumor cells in vivo, using HN5 and BT474 xenograft models. The ability of GW2016 to inhibit the HN5 tumor xenograft is similar to that reported for OSI-774 (7). GW2016 treatment can achieve tumor growth inhibition in the BT474 xenograft model that is similar to the efficacy of Herceptin monotherapy (28).

GW2016 is a novel inhibitor of EGFR and ErbB-2 kinase activity. In EGFR-overexpressing cell lines, the ability of GW2016 to inhibit growth is equal to that of small molecule EGFR inhibitors presently in clinical trials. In ErbB-2-overexpressing cells, GW2016 is much more potent at inhibiting cell growth than are the EGFR inhibitor clinical candidates tested. Therefore, we believe that GW2016 has the potential to benefit cancer patients with tumors overexpressing either EGFR, ErbB-2, or both of these receptors together.

Acknowledgments
We thank Perry S. Brigolina for providing purified EGFR, ErbB-2, and ErbB-4. We also thank Neal Bramson, Laurie Kane, Wendy Liu, Brad McDonald, Justin Mitchell, Frank Preugschat, Stephanie Schweiker, Darren Stuart, Gaociao Tian, Anne Truesdale, John Van Arnold, and Malcolm Willson for enzyme selectivity testing. Finally, we thank Jean Scott for editorial assistance in the preparation of this manuscript.

References
5. Swaisland, H., Laight, A., Stafford, L., Jones, H., Morris, C., Dane, A., and Yates, R. Pharmacokinetics and tolerability of the orally active selec-


Molecular Cancer Therapeutics

The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo

David W. Rusnak, Karen Lackey, Karen Affleck, et al.


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/1/2/85

Cited articles
This article cites 36 articles, 19 of which you can access for free at:
http://mct.aacrjournals.org/content/1/2/85.full.html#ref-list-1

Citing articles
This article has been cited by 92 HighWire-hosted articles. Access the articles at:
/content/1/2/85.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.